A Dose-escalation and Dose-expanded Phase I/II Clinical Study to Evaluate the Safety, and Efficacy of FT-003 in Subjects With Wet AMD
Latest Information Update: 17 Jul 2024
At a glance
- Drugs FT 003 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Frontera Therapeutics
Most Recent Events
- 17 Jul 2024 New trial record